GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citius Oncology Inc (NAS:CTOR) » Definitions » Gross Profit

CTOR (Citius Oncology) Gross Profit : $0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Citius Oncology Gross Profit?

Citius Oncology's gross profit for the six months ended in Sep. 2024 was $0.00 Mil. Citius Oncology's gross profit for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Citius Oncology's gross profit for the six months ended in Sep. 2024 was $0.00 Mil. Citius Oncology's Revenue for the six months ended in Sep. 2024 was $0.00 Mil. Therefore, Citius Oncology's Gross Margin % for the quarter that ended in Sep. 2024 was N/A%.

Citius Oncology had a gross margin of N/A% for the quarter that ended in Sep. 2024 => No sustainable competitive advantage


Citius Oncology Gross Profit Historical Data

The historical data trend for Citius Oncology's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citius Oncology Gross Profit Chart

Citius Oncology Annual Data
Trend Sep22 Sep23 Sep24
Gross Profit
- - -

Citius Oncology Semi-Annual Data
Sep22 Sep23 Sep24
Gross Profit - - -

Competitive Comparison of Citius Oncology's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Citius Oncology's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Citius Oncology's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Citius Oncology's Gross Profit distribution charts can be found below:

* The bar in red indicates where Citius Oncology's Gross Profit falls into.



Citius Oncology Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Citius Oncology's Gross Profit for the fiscal year that ended in Sep. 2024 is calculated as

Gross Profit (A: Sep. 2024 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Citius Oncology's Gross Profit for the quarter that ended in Sep. 2024 is calculated as

Gross Profit (Q: Sep. 2024 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Gross Profit for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Citius Oncology's Gross Margin % for the quarter that ended in Sep. 2024 is calculated as

Gross Margin % (Q: Sep. 2024 )=Gross Profit (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Citius Oncology  (NAS:CTOR) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Citius Oncology had a gross margin of N/A% for the quarter that ended in Sep. 2024 => No sustainable competitive advantage


Citius Oncology Gross Profit Related Terms

Thank you for viewing the detailed overview of Citius Oncology's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Citius Oncology Business Description

Traded in Other Exchanges
N/A
Address
11 Commerce Drive, First Floor, Cranford, NY, USA, 07016
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.